Pharmaceuticals Industry Deals and Trends in March 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

GlobalData's "Pharmaceuticals Industry Deals and Trends in March 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market.

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2021 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2021 12

2.2.1 Helsinn Group to Enter into Licensing Agreement with QED Therapeutics 12

2.2.2 Amgen to Acquire Five Prime Therapeutics 13

2.2.3 Altaris Capital Partners to Acquire Generic Rx Pharma Business from Perrigo 13

2.2.4 Anima Biotech Enters into Co-Development Agreement with Takeda Pharma 14

2.2.5 Merck to Enter into Licensing Agreement with Debiopharm 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2021 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2021 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2021 17

3.1.1 Top M&A Deals in March 2021 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2020- March 2021 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2021 20

3.2.1 Top Equity Offering Deals in March 2021 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2020- March 2021 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2021 24

3.3.1 Top PE/VC Deals in March 2021 25

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2021 26

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2021 27

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, October 2020-March 2021 28

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2020-March 2021 29

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2021 30

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2020- March 2021 31

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2021 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2021 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2020- March 2021 36

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2020- March 2021 37

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2020- March 2021 38

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2021 40

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2021 40

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2021 41

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2020- March 2021 42

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2020- March 2021 43

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2020- March 2021 45

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2020- March 2021 47

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2021 48

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2021 49

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2021 49

5 & Healthcare, Global, Deal Summary by Therapy Area 50

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2021 50

5.1.1 Oncology – Deals of the Month 51

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2021 53

5.2.1 Central Nervous System – Deals of the Month 55

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2021 56

5.3.1 Infectious Diseases – Deals of the Month 58

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2021 59

5.4.1 Cardiovascular – Deals of the Month 60

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2021 61

5.5.1 Immunology – Deal of the Month 62

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, March 2021 63

5.6.1 Metabolic- Deals of the Month 64

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, March 2021 65

5.7.1 Gastrointestinal – Deals of the Month 66

6 Deal Summary by Geography 68

6.1 Pharmaceuticals & Healthcare, North America Deals, March 2021 68

6.1.1 North America – Deals of the Month 69

6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2021 73

6.2.1 Europe – Deals of the Month 74

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, March 2021 76

6.3.1 Asia-Pacific – Deals of the Month 77

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2021 79

6.4.1 Rest of the World – Deals of the Month 80

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 82

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2020- March 2021 82

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2020- March 2021 83

8 Further Information 84

8.1 Methodology 84

8.2 About GlobalData 85

8.3 Contact Us 85

8.4 Disclosure information 85

8.5 Disclaimer 86

List of Tables

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2021 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2021 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2021 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2021 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 23

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 25

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2021 25

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2020- March 2021 26

Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2021 28

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2020- March 2021 29

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2020- March 2021 29

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2020- March 2021 30

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2021 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 35

Table 21:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021 37

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2020- March 2021 39

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 40

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 41

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021 42

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2021 44

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, October 2020- March 2021 46

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2021 48

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2021 48

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2021 49

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2021 49

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 51

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 54

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 57

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 60

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 62

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 64

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 66

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 69

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 74

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 77

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 80

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2020- March 2021 82

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2020- March 2021 83

List of Figures

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2020- March 2021 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), March 2021 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2021 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2020- March 2021 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2020- March 2021 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2020- March 2021 24

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021 26

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals (%), March 2021 27

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2021 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2020- March 2021 28

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2020- March 2021 30

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2020- March 2021 38

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2020- March 2021 40

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 41

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021 42

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021 43

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number of Deals, October 2020- March 2021 45

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2020- March 2021 46

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2021 47

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2020- March 2021 50

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2020- March 2021 53

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2020- March 2021 56

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2020- March 2021 59

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2020- March 2021 61

Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 63

Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021 65

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2020- March 2021 68

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2020- March 2021 73

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2020- March 2021 76

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2020- March 2021 79

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2020- March 2021 82

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2020- March 2021 83

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports